Entrada Therapeutics, Inc. (TRDA)
$17.02
Live
Performance
- $16.80$17.49$17.02
1.29%
Downside
Day's Volatility :3.95%
Upside
2.69%
- $10.75$18.17$17.02
36.84%
Downside
52 Weeks Volatility :40.84%
Upside
6.33%
Returns
| Period | Entrada Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 1.93% | 3.6% | 0.0% |
6 Months | 33.13% | 10.2% | 0.0% |
1 Year | 15.04% | 19.6% | 0.0% |
3 Years | -27.18% | 16.8% | -23.0% |
Highlights
Market Capitalization | 655.8M |
Book Value | $12.22 |
Earnings Per Share (EPS) | 3.02 |
PE Ratio | 5.84 |
Wall Street Target Price | 21.5 |
Profit Margin | 43.63% |
Operating Margin TTM | 56.42% |
Return On Assets TTM | 10.86% |
Return On Equity TTM | 32.8% |
Revenue TTM | 239.4M |
Revenue Per Share TTM | 7.13 |
Quarterly Revenue Growth YOY | 421.2% |
Gross Profit TTM | 0.0 |
EBITDA | 96.9M |
Diluted Eps TTM | 3.02 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.45 |
EPS Estimate Next Year | -3.45 |
EPS Estimate Current Quarter | 0.14 |
EPS Estimate Next Quarter | -0.64 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 26.32%
Technicals Summary
Sell
Neutral
Buy
Entrada Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Entrada Therapeutics, Inc. | 19.7% | 33.13% | 15.04% | -27.18% | -27.18% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Entrada Therapeutics, Inc. | 5.84 | 5.84 | NA | 0.45 | 0.33 | 0.11 | NA | 12.22 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Entrada Therapeutics, Inc. | Buy | $655.8M | -27.18% | 5.84 | 43.63% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Entrada Therapeutics, Inc.
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 64.4%
Institutional Holdings
Baker Bros Advisors LP
13.08%Mpm Asset Management, LLC
11.90%5AM Venture Management, LLC
11.85%T. Rowe Price Associates, Inc.
8.43%FMR Inc
4.92%BlackRock Inc
4.55%
Company Information
entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.
Organization | Entrada Therapeutics, Inc. |
Employees | 168 |
CEO | Mr. Dipal Doshi |
Industry | Services |
